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Down-regulation of placental neuropilin-1 in fetal growth restriction
Dev Maulik, MD, PhD; Alok De, PhD; Louis Ragolia, PhD; Jodi Evans, PhD; Dmitry Grigoryev, MD, PhD;
Kamani Lankachandra, MD; David Mundy, MD; Jolene Muscat, MD; Mary M. Gerkovich, PhD;
Shui Qing Ye, MD, PhD

Introduction
Associated with adverse outcomes spanning fetal to adult life, fetal growth restriction (FGR) constitutes a major
obstetrical complication affecting 5-7% of
all pregnancies.1,2 Perinatal mortality is
substantially high in FGR and approximately 1 in 4 of the stillborn fetuses is
growth restricted. Perinatal morbidities
Cite this article as: Maulik D, De A, Ragolia L, et al.
Down-regulation of placental neuropilin-1 in fetal growth
restriction. Am J Obstet Gynecol 2016;214;279.e1-9.
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was used with P < .05 considered statistically significant. Independent
groups t test was used to analyze the immunostain intensity scores with a
P < .05 considered statistically significant.
RESULTS: Our microarray results showed that among several differentially expressed angiogenic genes in the growth-restricted group, only
the down-regulation of neuropilin (NRP)-1 was most significant (P <
.0007). Quantitative real-time polymerase chain reaction confirmed a
significantly lower NRP-1 gene expression in the FGR group than in the
control group (mean  SD cycle threshold: 0.624  0.55 and 1.325 
0.84, respectively, P ¼ .04). Western blot validated significantly lower
NRP-1 protein expression in the FGR group than in the control group
(mean  SD NRP-1/b-actin ratio: 0.13  0.04 and 0.34  0.05,
respectively, P < .001). Finally, immunohistochemistry of placental villi
further corroborated a significantly decreased expression of NRP-1 in the
FGR group (P ¼ .006).
CONCLUSION: The study demonstrated significant down-regulation
of placental NRP-1 expression in FGR pregnancies complicated with
AEDF in umbilical artery. As NRP-1 is known to promote sprouting
angiogenesis, its down-regulation may be involved in the deficient
vascular branching observed in FGR placentas suggesting the presence of an antiangiogenic state. Further studies may elucidate such a
causal role and may lead to the development of novel diagnostic and
therapeutic tools.
ˇ

BACKGROUND: Fetal growth restriction (FGR) is associated with
adverse outcomes extending from fetal to adult life, and thus, constitutes a
major health care challenge. Fetuses with progressive growth restriction
show increasing impedance in the umbilical artery flow, which may
become absent during end-diastole. Absent end-diastolic flow (AEDF) is
associated with adverse perinatal outcomes including stillbirths and
perinatal asphyxia. Placentas from such pregnancies demonstrate deficient fetoplacental vascular branching. Current evidence, moreover, indicates an antiangiogenic state in maternal circulation in several
pregnancy complications including preeclampsia, small-for-gestationalage births, fetal death, and preterm labor. The angiogenic mediators in
maternal circulation are predominantly of placental origin. Information,
however, on the role of specific proangiogenic and antiangiogenic
mechanisms operating at the placental level remains limited. Elucidation of
these placenta-specific angiogenic mechanisms will not only extend our
understanding of the causal pathway for restricted fetal growth but may
also lead to the development of biomarkers that may allow early recognition of FGR.
OBJECTIVE: We sought to test the hypothesis that fetoplacental
angiogenic gene expression is altered in pregnancies complicated with
FGR and umbilical artery Doppler AEDF.
STUDY DESIGN: Placental samples were collected from FGR pregnancies complicated with umbilical artery Doppler AEDF (study group,
n ¼ 7), and from uncomplicated pregnancies (control group, n ¼ 7), all
delivered by cesarean during the last trimester of pregnancy. Angiogenic
oligonucleotide microarray analysis was performed and was corroborated
by quantitative real-time polymerase chain reaction, Western blot analysis,
and immunohistochemistry. The Student t test with Bonferroni correction

Key words: antiangiogenic state, fetal growth restriction, immunohis-

tochemistry, microarrays, neuropilin-1, placental branching angiogenesis,
real-time polymerase chain reaction, small for gestational age, umbilical
artery absent end-diastolic flow

include asphyxia, preterm delivery,
neonatal depression, and a spectrum of
metabolic, respiratory, and neurological
complications. Long-term risks include
continuing growth deﬁcit, cerebral
palsy, and neurodevelopmental abnormalities.3-6 Beyond the perinatal period
and infancy, adverse consequences of
FGR extend into adult life. Experimental
and epidemiological evidence indicates
that chronic intrauterine deprivation may
induce epigenetic programming and a
thrifty phenotype setting the stage for
subsequent development of adult illnesses
including hypertension, stroke, ischemic
heart disease, type 2 diabetes, and central
obesity.7 Constrained fetal growth thus
constitutes a major health care concern.

Compromised fetal supply line has
long been proposed as a major underlying mechanism for limiting fetal
growth.8,9 Consistent with this concept,
Doppler ultrasound studies have shown
increasing umbilical circulatory impedance associated with progressive fetal
decompensation in FGR, eventually
leading to absent end-diastolic ﬂow
(AEDF) in the umbilical artery.10 This
hemodynamic deterioration is associated with a spectrum of adverse perinatal
outcomes including stillbirths and perinatal asphyxia.11,12 There is morphological evidence, moreover, correlating
umbilical artery AEDF to diminished
fetoplacental vascular branching in
FGR pregnancies.13,14 The molecular
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mechanisms underlying aberrant fetoplacental angiogenesis in FGR, however,
require further elucidation.
Angiogenesis is a complex biological
process controlled by agonists and antagonists directly or indirectly promoting
or inhibiting angiogenic activity. Normal
pregnancy represents a balanced angiogenic state. Current evidence, however,
indicates the presence of an antiangiogenic state in several pregnancy
complications. Maynard et al15 ﬁrst proposed an antiangiogenic state in preeclampsia involving up-regulation of
soluble fms-like tyrosine kinase-1 of
placental origin in maternal plasma,
which opposes proangiogenic vascular
endothelial growth factor (VEGF) and
placental growth factor (PlGF). Subsequently, the Romero group16-22 has provided extensive evidence for the presence
of an antiangiogenic state in maternal
circulation in several pregnancy disorders
including
preeclampsia,
small-forgestational-age (SGA) births, fetal death,
and preterm labor, and in association with
placental massive perivillous ﬁbrin
deposition, a condition known to be
associated with recurrent miscarriage and
stillbirths. Others also have documented
an antiangiogenic state in pregnancies
resulting from in vitro fertilization,23
obesity,24 twin transfusion syndrome,25
and invasive placentation.26 Moreover,
there is evidence that antiangiogenic
agents in maternal serum may serve as
potential biomarkers for subsequent
recognition of fetal growth compromise
and adverse pregnancy outcomes.27-29
These angiogenic mediators in
maternal circulation are predominantly of
placental origin. Information, however,
on the role of speciﬁc proangiogenic and
antiangiogenic mechanisms operating at
the placental level remains limited.30,31
Elucidation of these placenta-speciﬁc
angiogenic mechanisms will not only
extend our understanding of the causal
pathway for restricted fetal growth but
may also lead to the development of biomarkers for FGR that may allow early
recognition of FGR and differentiation of
constitutionally small fetuses from those
that are truly growth restricted. The latter
currently remains challenging despite
advances in fetal sonography. Such

mechanistic understanding may also lead
to the emergence of new management
strategies for promoting fetal growth.
The purpose of this study, therefore,
was to investigate the placental angiogenic mechanisms in FGR pregnancies
complicated with fetal hemodynamic
compromise as evidenced by umbilical
artery AEDF. Speciﬁcally, we determined
in these pregnancies placental expressions of angiogenic genes utilizing
oligonucleotide microarray analysis, and
to conﬁrm the signiﬁcant array ﬁndings
of differentially expressed messenger
RNA (mRNA) transcripts by quantitative real-time polymerase chain reaction
(qPCR), Western Blot analysis of protein
expression, and immunohistochemistry
for localization and quantiﬁcation in
placental tissues.

chorioamnionitis; placental pathology
such as abruption, placenta previa, and
placental accreta; and maternal diseases
such as infection, diabetes, and chronic
hypertension. The control group included
uncomplicated pregnancies, matched by
gestational age with the study group, and
delivered by elective cesarean delivery
before labor indicated by previous cesarean delivery or breech presentation. The
birthweight centile was determined utilizing the US national reference values as
reported by Oken et al.35 The institutional
review boards of Truman Medical Center/
University of MissourieKansas City
School of Medicine and Winthrop University Hospital approved the study.
Informed consent was obtained from
each patient according to the institutional
review board protocol.

Materials and Methods
Study design

Placental sample acquisition

In this prospective study, angiogenic gene
expression was analyzed on placental
samples collected from pregnancies
complicated with FGR and umbilical artery Doppler AEDF (study group, n ¼ 7),
and from uncomplicated pregnancies
(control group, n ¼ 7). FGR was deﬁned
as an ultrasound-estimated fetal weight
<10th percentile for gestational age
following the American Congress of Obstetricians and Gynecologists (ACOG)
guidelines.32 We followed these guidelines
to restrict the terms “fetal growth restriction” to the fetus and “small for
gestational age” to the neonate. Pregnant
mothers receiving prenatal care were
approached for consent and participation
in the study. The inclusion criteria for the
study group were: singleton pregnancies,
gestational age ascertained according to
the ACOG guidelines,33 gestational age
>36 weeks, ultrasound biometric diagnosis of FGR, AEDF in the umbilical artery Doppler, and delivery by cesarean
delivery. This mode of delivery was chosen to minimize possible placental
oxidative stress from labor and delivery as
demonstrated by others.34 The exclusion
criteria were labor; pregnancy complications other than FGR such as preeclampsia, multiple gestation, fetal
aneuploidy, fetal malformations, prolonged rupture of membranes, and

Within 10 minutes after the placental
delivery, placental tissue samples were
collected using a sterile scalpel. Three
samples each measuring approximately
2  2  2 cm were removed from a
mediobasal location as deﬁned by Wyatt
et al.36 Each sample was then divided into
3 identical pieces, rinsed thoroughly in
sterile phosphate buffer solution, and
snap-frozen in liquid nitrogen. The samples were stored in a biorepository according to the institutional regulations.

Angiogenesis gene array analysis
Two angiogenesis-oriented arrays were
used for gene expression analysis.
Angiogenic SuperArray HS-009 contained 96 genes and 16 internal controls
and angiogenic SuperArray OHS-024
contained 114 genes and 14 internal
controls (SuperArray Biosciences Corp,
Frederick, MD).
The total RNA was extracted from
placental tissues using Trizol (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. RNA samples (3 mg) were then reverse transcribed
and labeled with biotin-16-dUTP
(Roche, Nutley, NJ) by polymerase
chain reaction (PCR) using the
AmpoLabeling-LPR kit (SuperArray
Biosciences Corp). Then, probes were
hybridized to either GEArray HS-009 or
GEArray OHS-024. The hybridization
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signals were generated by GEArray
chemiluminescent detection kit (SuperArray Biosciences Corp) and evaluated
by the Kodak Image Station 4000R and
the ChemiDoc XRS (BioRad Laboratories, Hercules, CA), respectively. The
relative expression levels of angiogenesis
gene were normalized to a panel of
housekeeping genes of the corresponding array and cross-linked using gene
symbols.

qPCR analysis
qPCR analysis was used to conﬁrm the
signiﬁcant angiogenic ﬁndings of the
differentially expressed mRNA transcripts (SuperArray Biosciences Corp).
Total RNA (1.5 mg/sample) was reverse
transcribed using the First Strand cDNA
synthesis kit according to manufacturer’s
instructions (Roche). The primers were
designed using the Primer3 software
(MIT) for sense and antisense and purchased from Origene Technologies
(Rockville, MD). The sequences of forward and reverse primers were: human
GAPDH (GenBank accession no.
NM_002046) 50 CTCTCTGCTCCTCC
TGTTCGAC 30 and 50 TGAGCGATGT
GGCTCGGCT 30 and human neuropilin
(NRP)-1 (GenBank accession no.
NM_001024628) 50 ACG ATG AAT GTG
GCG ATA CT 30 and 50 AGT GCA TTC
AAG GCT GTT GG 30 . Real-time qPCR
was performed by using Fast SYBR Green
on a StepOne Plus real-time PCR system
(Applied Biosystems, Grand Island, NY).
Relative expression values were calculated
using the 2-delta delta Ct method and
were normalized against reference gene
GAPDH. In these calculations we
accounted for the PCR efﬁciency of the
individual PCR reactions, calculated on
the basis of linear regression as described
elsewhere.37 The speciﬁcity of ampliﬁcation was conﬁrmed by evaluation of the
melting curve.

protein was transferred onto nitrocellulose membrane. The membrane was
blocked with blocking serum (Thermoscientiﬁc, Waltham, MA) followed
by incubation with mouse antihuman
NRP-1 antibody (1:1000) (Abcam,
Cambridge, MA) overnight at 4 C.
After washing with Tris-NaCl-tween
20 buffer, the membrane was incubated with antimouse IgG (1:15000)
(Abcam) at room temperature for 1
hour. Immunoreactivity was detected
using an enhanced chemiluminescence
Western blotting system (Thermoscientiﬁc). Qualitative analysis was
performed and expressed in relation
to b-actin.

Immunohistochemical localization
and quantification
The placental tissues were ﬁxed in 4%
buffered formaldehyde solution, dehydrated, and embedded in parafﬁn. The 4mm thickness sections were transferred
onto poly-l-lysin-coated slides, deparafﬁnized, rehydrated, and immunostained with NRP-1 antibody (1:200)
using the Vectastain Immpress Reagent
Kit (Vector Laboratories, Burlingame,
CA). Two investigators blinded to the
sample source independently graded
immunostain intensity. Slides were ﬁrst
examined at 4 magniﬁcation to identify
NRP-1 immunopositive regions in
placental sections. In each section, 5
different areas with 8-12 villi per area were
selected at random and were evaluated
microscopically with a 40 objective
magniﬁcation. All sections were scored in
a semiquantitative fashion as described by
Hsu et al,38 which considered both the
intensity and percentage of cells staining.
Intensities were classiﬁed as 0 (no
staining), þ1 (weak staining), þ2 (moderate staining), and þ3 (very strong
staining).

Statistics
Protein extraction and Western blot
The protein was extracted from
placental samples and its concentration
was measured by the BCA protein assay
method per manufacturer’s protocol
(Pierce, Rockford, IL). Each sample (50
mg) was separated in 10% sodium
dodecyl sulfate-polyacrylamide gel. The

Angiogenic data (SuperArray Biosciences Corp) were normalized to corresponding internal controls and
resulting gene expression values were
cross-referenced between arrays. The
Student t test was applied to 67 genes
that were common to both SuperArrays
and genes with P < .05 considered

Original Research

signiﬁcant. The ﬁnal candidate selection
was done by ﬁltering for the Bonferroni
correction for multiple comparisons (P
< .0007). The values from qPCR were
adjusted to GAPDH, and the values from
Western blot were adjusted for b-actin,
then mean and SD values were determined. The immunostain intensity met
the distributional assumptions of a
parametric statistical test. Independent
groups t test was used to compare the
control and FGR groups for these values.
Differences were considered signiﬁcant
when P was <.05.

Results
Clinical characteristics
The basic clinical characteristics of the
control and the FGR groups are presented in the Table. There were no differences between the groups regarding
maternal age and gestational age. The
population was racially diverse and the
sample size did not permit any analysis
of the impact of race. Notably, this was
not an objective of this study. The
birthweights and the placental weights
were signiﬁcantly lower in the FGR
group than those in the control group.
The birthweights were <5th centile for
the study group and >20th centile for
the control group. There were no fetal
deaths in this population.

Down-regulation of placental
NRP-1 mRNA expression in FGR
To investigate that placenta-speciﬁc
angiogenic mechanisms may underlie
restricted fetal growth, we ﬁrst determined expressions of genes in angiogenic
pathway using 2 angiogenesis-oriented
arrays (SuperArray Biosciences Corp
and Qiagen, Valencia, CA). Several
angiogenesis-related genes were differentially expressed in placentas from FGR
pregnancies. A representative microarray
photograph depicts expression of angiogenic genes in control and FGR in
Figure 1, A. Densitometric analysis
showed signiﬁcant reduction in NRP-1 in
FGR placentas (Figure 1, B). A heat map
depicting the results obtained in control
and FGR placentas is shown in Figure 1,
C. The scatter plot shown in Figure 1, D,
demonstrates underexpression and overexpression of genes in FGR placentas.
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TABLE

Clinical characteristics of control and fetal growth restriction groups
Parameter

Control (n ¼ 7)

FGR (n ¼ 7)

Significance

Maternal age, y

26.57  2.60

25.71  1.85

NS

Gestational age, wk

39  0.85

37.46  0.86

NS

Birthweight, g
Placental weights, g

3181.86  234.31

2377.86  72.88

P < .01

563.66  43.17

217.60  54.58

P < .001

Values are mean  SEM.
FGR, fetal growth restriction; NS, not significant.
Maulik et al. Placental neuropilin-1 in fetal growth restriction. Am J Obstet Gynecol 2016.

Although several genes in the study
group were down-regulated by >30% of
those in the control group, only NRP-1
was inhibited by >2-fold (Figure 2).
When the gene expression proﬁles of
the 2 microarray platforms, SuperArray
HS-009
and
SuperArrayOHS-024
(SuperArray Biosciences Corp), were
cross-referenced and ﬁltered by Student t
test, only 3 genes were signiﬁcantly
underexpressed, of which only NRP-1
remained signiﬁcant (P < .0007) when
further ﬁltering was performed by

FIGURE 1

Fetal growth restriction (FGR) reduces expression of angiogenesis-related genes in FGR placentas

A, Representative photograph of microarrays from control and FGR placentas; expression of neuropilin (NRP)-1 (arrows). B, Histogram showing reduced
expression of NRP-1 in FGR placentas compared to controls. Values are mean  SEM of densitometric ratios of NRP-1 and GAPDH. C, Representative
heat map of angiogenesis-related genes from control and FGR placentas (left). Magnification of selected area of heat map showing NRP-1 expression
status (right). Magnitude of gene expression (far right). D, Representative scatterplot of angiogenic gene expression in FGR vs control placentas. Genes
were either underexpressed (green) or overexpressed genes (red) in FGR placentas. * P < 0.05, as compared with the control group.
Maulik et al. Placental neuropilin-1 in fetal growth restriction. Am J Obstet Gynecol 2016.
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FIGURE 2

FIGURE 3

FIGURE 4

Relative expression of 11 downregulated angiogenic genes in
fetal growth restriction (FGR)
placentas

Identification of fetal growth
restriction candidate genes

Quantitative real-time polymerase
chain reaction (qPCR) analysis of
neuropilin (NRP)-1 genes in
control and fetal growth
restriction (FGR) placentas

Maulik et al. Placental neuropilin-1 in fetal growth restriction. Am J Obstet Gynecol 2016.

ˇ

Vertical axis shows expression level ratios of
each gene to GAPDH in both control and FGR
groups. Horizontal axis depicts 11 downregulated angiogenic genes in FGR placentas.
Arrow highlights neuropilin-1 down-regulation.

Gene expression profiles of 2 microarray platforms were cross-referenced. SuperArray HS009 is depicted as array 1 and
SuperArrayOHS-024 as array 2 (SuperArray
Biosciences Corp, Frederick, MD). Student t test
was used on genes that were common to both
microarrays. Final candidate selection was done
by Bonferroni correction for multiple
comparisons.

Differential NRP-1 gene expression by qPCR in
placentas from control and FGR groups. Relative
expression values were calculated using 2-delta
delta Ct method and were normalized against
reference gene GAPDH. Data are mean  SD
values of average mean of delta or difference in
cycle threshold ( ct) values in 7 control and 7
FGR placentas. *P < .05, significantly different
from control group.
Maulik et al. Placental neuropilin-1 in fetal growth restriction. Am J Obstet Gynecol 2016.

Maulik et al. Placental neuropilin-1 in fetal growth restriction. Am J Obstet Gynecol 2016.

Bonferroni correction for repeated measures (Figure 3).
To conﬁrm the microarray ﬁndings
by alternative approach, we quantiﬁed
placental NRP-1 by qPCR. It demonstrated signiﬁcantly lower NRP-1 gene
expression in the FGR group compared
to the control group (Figure 4). The
cycle threshold mean (SD) was 0.624
 0.55 for the FGR group, and 1.325 
0.84 for the control group and the difference was signiﬁcant (P ¼ < .05).
ˇ

Validation of placental NRP-1
protein expression by Western
blot analysis and
immunohistochemistry
To validate placental down-regulated
NRP-1 protein expression, we performed Western blot and immunohistochemical analysis. Western blot
analysis showed that the expression of
NRP-1 was reduced in FGR placentas
(Figure 5). Loading error was determined with b-actin. Densitometric
analysis of Western blot showed reduced
expression of NRP-1 in FGR placentas
(Figure 5). NRP-1 protein expression,
measured as NRP-1/b-actin ratio, was
signiﬁcantly lower in the FGR samples

than in the control samples (0.13  0.04
vs 0.34  0.05, P < .001).
Immunohistochemistry for the localization of NRP-1 protein in placental
tissue revealed strong immunoreactivity
in cytotrophoblasts of the placental villi
(Figure 6, A and B). NRP-1 immunoreactivity was also found in the vascular
endothelium of placental stem vessels,
Hofbauer cells, and syncytiotrophoblast
cells (Figure 6). In the FGR group the
staining intensity was signiﬁcantly lower
in comparison to the control group: 2.6
 1.5 vs 8.9  4.2, respectively (P <.05).
We did not identify NRP-1 immunostaining in syncytial knots in either
group. Intensity scoring corroborated
signiﬁcant reduction (<.05) in the tissue
expression of NRP-1 in FGR placentas
(Figure 6, C).

showed that although various angiogenesis and related genes differentially
expressed, only the down-regulation of
NRP-1 from FGR placentas achieved
signiﬁcance compared to those from the
controls. This ﬁnding was validated by
qPCR and Western blot that showed
down-regulation of NRP-1 mRNA and
protein, respectively, in the FGR placentas. Decreased immune localization
of NRP-1 in the various components of
villous tissue in FGR placentas further
corroborated this. The relevance of our
ﬁnding lies with the existing evidence
that there is deﬁcient branching angiogenesis in fetal placental vascular system
in FGR with hemodynamic compromise13,14 and with the emerging evidence that NRP-1 plays an important
role in modulating sprouting angiogenesis through tip cell formation.39 These
are further addressed below.

Comment
Primary findings

Fetoplacental angiogenesis
and FGR

In this study, we demonstrate the downregulation of NRP-1 in placentas from
FGR pregnancies compared to those
from pregnancies with appropriate fetal
growth. The angiogenesis array data

In a human placenta, fetoplacental
vascular development begins at about 3
weeks postconception with vasculogenesis, which is the de novo formation of
ﬁrst vessels from multipotent angioblastic
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FIGURE 5

Western blot of control and fetal
growth restriction (FGR)
placentas

Upper panel shows representative photograph
of Western blot of neuropilin (NRP)-1. b-Actin
was included as housekeeping protein control
for each blot. Lower panel shows mean  SD
values of densitometric ratio of NRP-1 with bactin at bottom of each respective gel in 7
control and 7 FGR placentas. *P < .001.
Maulik et al. Placental neuropilin-1 in fetal growth restriction. Am J Obstet Gynecol 2016.

precursor cells, and continues until the
42nd day.40 Angiogenesis follows with the
generation of new vessels from the preexisting ones by either elongation or
branching, and the process continues
until the end of gestation. As reviewed by
Burton et al,30 there is substantial evidence suggesting continuing branching

angiogenesis throughout gestation in
human placenta. Our ﬁnding of NRP-1
expression in near-term placentas indirectly corroborates this. The expanding
fetoplacental vascular tree leads to a progressive decrease in the umbilical artery
vascular impedance and a concomitant
increase in the umbilical blood ﬂow,
which is essential for sustaining fetal
growth. As the arterial Doppler waveform
is shaped by vascular impedance,41 these
hemodynamic changes are reﬂected in the
rising end-diastolic ﬂow and falling pulsatility indices in the umbilical arterial
Doppler waveforms as pregnancy
advances.
This pattern of fetoplacental angiogenesis is perturbed in FGR. Placentas
from FGR pregnancies show signiﬁcant
reductions in peripheral villous capillary
and surface areas.42 Utilizing scanning
electron microscopy of perfusion-ﬁxed
villous tissue and vascular plastic cast,
it was demonstrated that in FGR pregnancies complicated with umbilical artery AEDF velocity, the terminal villi
showed signiﬁcant paucity in the number of capillaries as well as a decrease in
their branching.14 Further corroboration was provided by morphological
examination of the FGR placentas that
demonstrated progressive reductions in
fetal placental stem artery branching,
terminal villous branching, and

villous capillarization as the umbilical
artery end-diastolic ﬂow progressively
deteriorated and became absent or
reversed.15 These and similar observations establish a strong association between defective placental branching
angiogenesis, abnormal fetoplacental
circulatory dynamics, and fetal growth
compromise. The fetoplacental vascular
development involves multiple angiogenic agents and pathways involving
VEGF and related genes.43 Discovery of
the role of NRP-1 may further elucidate
the molecular regulation of fetoplacental
branching angiogenesis, especially in
pregnancies complicated with FGR.

Role of NRP-1 in angiogenesis
NRP-1, a single-pass transmembrane
glycoprotein, is essential for axonal
guidance in neuronal development and
for angiogenesis.44-46 Highly conserved
in the vertebrates, its molecular structure
consists of 3 regions: extracellular,
transmembrane, and intracellular. The
extracellular region contains 5 domains.
Domains a1 and a2 are N-terminal
binding CUB (C1r/C1s, urchin embryonic growth factor and bone morphogenic protein 1) domains, and bind
class-3 semaphorins, which are essential for axonal guidance. Domains b1 and
b2 are coagulation factors V and VII
homology domains, act as ligands for

FIGURE 6

Neuropilin (NRP)-1 immunoreactivities in control and fetal growth restriction (FGR) placentas

Representative photomicrograph showing reduced expression of NRP-1 immunostaining in FGR placentas. A, Control, B, FGR. C, Histogram shows
staining intensities of NRP-1 in control and FGR placental cells. Placentas were fixed and immunostained with NRP-1 antibody and photographed
at 400 magnification. Bar ¼ 50 mm. Values are mean  SD of 7 placentas from each group. *P < .05, as compared with control group. Arrows
indicate different cell types.
CT, cytotrophoblast; HC, Hofbauer cells; SK, syncytial knot; ST, syncytiotrophoblast; VE, vascular endothelium.
Maulik et al. Placental neuropilin-1 in fetal growth restriction. Am J Obstet Gynecol 2016.
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VEGF and class-3 semaphorins, and are
essential for angiogenesis.47 The b1
domain forms a complex with VEGF-2
(VEGF receptor 2 [VEGFR-2]), acts as
a holoreceptor for VEGF-165, and
stimulates angiogenesis. However, the
angiogenic role for NRP-1 is not entirely
dependent on VEGF. Fantin and associates demonstrated angiogenic capability
of NRP-1 without VEGF interaction in a
NRP-1 hypomorphic mice knock-in
model.48 Alternative suggested pathways for NRP-1 action include p130
(Cas) tyrosine phosphorylation that involves the intracellular domain of NRP1.49 Lanahan et al50 and others have
shown that the intracytoplasmic C
domain of NRP-1 molecule containing
the PDZ binding site facilitates intracellular VEGFR-2 trafﬁcking, which promotes ERK1/2 signaling and stimulates
arteriogenesis. In human, primate, and
mouse circulations, soluble NRP-1
molecules, expressing either the complete extracellular domain or parts of the
domain, have been identiﬁed.51,52 These
soluble forms of NRP-1 offer potential
opportunities for developing biomarkers
for FGR, although their functional signiﬁcance in developmental angiogenesis
remains to be elucidated.
There is evidence that the NRP-1
molecule may be involved in tip cell
formation, which constitutes an
essential initial step in sprouting
angiogenesis.53 In response to an
angiogenic signal, a subset of dormant
endothelial cells of a vessel loses pericyte cover, becomes less adherent to the
adjoining cells and the basement
membrane, and is ready to migrate.
The migration is led by the tip cell,
which is an endothelial cell modiﬁed by
the presence of several angiogenesisrelated molecules. Once a tip cell is
formed, the adjacent endothelial cells
preferentially become stalk cells and
proliferate to form the stalk of the
vessel branch. Whereas VEGF, VEGFR2, and NRP-1 promote tip cell formation, NOTCH ligands DLL4 and JAGGED1 act as inhibitors of tip cells and
promoters of stalk cells, and their dynamic balance guide tip cell and stalk
cell differentiation. Under the effects of
vascular endothelium-cadherin, VEGF,

and other molecules, the stalks develop
lumens and form a vascular sprout.
The above steps in sprouting angiogenesis have not yet been demonstrated
in human fetal placental vascular development although there is evidence that
NRP-1 plays a role in modulating
decidual vascular development in early
gestation in a mouse model and in human beings.54,55 In light of the known
role of NRP-1 as a vessel guidance cue in
sprouting angiogenesis, our ﬁnding that
NRP-1 is signiﬁcantly down-regulated in
FGR placentas suggests that it may play a
role in deﬁcient fetoplacental vascular
branching in FGR pregnancies. Similar
to FGR, preeclampsia is also characterized by deﬁcient fetoplacental vascular
branching and an antiangiogenic state.
The role of NRP-1 in preeclampsia,
however, remains to be elucidated. Zhou
et al56 recently demonstrated in an
in vitro study that, in severe preeclampsia, cytotrophoblasts overexpress class3B semaphorins, a transmembrane and
secreted protein that competitively
blocks VEGF binding to NRP-1 and
NRP-2, leading to suppression of cytotrophoblastic invasion and promotion of
antiangiogenic activity. However, this
ﬁnding has been contested in a more
recent report.57 Further studies are
needed to clarify this issue.

FGR and antiangiogenic state
Our discovery of placental underexpression of NRP-1, a molecular agent
known to promote branching angiogenesis, suggests that an antiangiogenic
state prevails also at the placental level
in FGR pregnancies complicated with
fetal hemodynamic compromise. This
observation is consistent with the previous demonstration that an antiangiogenic state exists in several
pregnancy disorders including preeclampsia and, more relevantly, SGA
births. These are brieﬂy discussed below.
In a longitudinal nested case-control
study involving 144 singleton pregnancies, Romero et al17 observed that the
maternal plasma levels of antiangiogenic
agent soluble endoglin (s-Eng) was
up-regulated and proangiogenic agent
PlGF was down-regulated prior to the
development of preeclampsia and SGA

Original Research

births. In another longitudinal casecontrol study involving 402 singleton
pregnancies, the same group measured
s-Eng, soluble VEGFR-1 (sVEGFR-1),
and PlGF and their ratios between the
ﬁrst and second trimesters of pregnancy.16 Again, an increase in the antiangiogenic state was evident as the
up-regulation of s-Eng and the downregulation of PlGF was associated with
a greater propensity to the development
of preeclampsia and SGA births. There
was, however, no observed association
between sVEGFR-1 levels and the risk of
SGA. In general the antiangiogenic state
was more pronounced in preeclampsia
than in SGA. Further corroboration was
provided by a cross-sectional study
involving 340 pregnant mothers in
whom plasma levels of the soluble receptor tyrosine kinase Tie-2 were
measured.58 Tie-2 promotes angiogenesis in conjunction with angiopoietin
system, a component of the VEGF family. The levels were lower in preeclampsia
and in SGA births suggesting an antiangiogenic milieu in these disorders.
Finally, our ﬁnding is consistent with a
previous report by Chaiworapongsa
et al,59 who demonstrated that in pregnancies with SGA births, an association
exists between abnormal uterine and
umbilical artery Doppler and a higher
maternal plasma concentrations of
sVEGFR-1, a known antiangiogenic
molecule. Furthermore, the same group
more recently demonstrated that in
singleton pregnancies between 24-34
weeks with suspected SGA, angiogenic
and antiangiogenic factors in maternal
plasma could predict subsequent development of preeclampsia or indicated
early preterm delivery in most women.60

Strengths of the study
There are several strengths to our study.
The study was prospective with a welldeﬁned population. The gestational age
was determined in early pregnancy; ultrasound biometric determination of
FGR was according to national guidelines; and the evidence of fetoplacental
hemodynamic compromise as reﬂected
in the Doppler AEDF further deﬁned the
population. The study and control populations were matched by gestational
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age, and only cesarean deliveries
were included. The latter approach
minimized the risk of altered placental
angiogenic gene expression from periodic placental ischemia and hypoxia
caused by uterine contractions, which
was reported by Cindrova-Davies et al.34
We collected tissue samples from the
mediobasal location of the placental disk
as deﬁned by Wyatt et al36 who demonstrated that the sampling site signiﬁcantly affected hypoxia-related genes
including VEGF in term placentas. The
mediobasal area is well perfused, less
likely to express hypoxia-induced
angiogenic gene expression, and most
likely to have normal branching
angiogenesis.

distinction is not possible with the current
diagnostic approaches. Future potential
also exists for therapeutic innovations
speciﬁcally targeting deﬁcient placental
NRP-1 expression. Furthermore, as FGR
with umbilical artery AEDF shows deﬁcient placental branching angiogenesis
and as NRP-1 is involved in vascular
sprouting, we speculate that NRP-1 plays
a signiﬁcant role in fetoplacental branching angiogenesis and its down-regulation
may be mechanistically involved in
abnormal vascular development in FGR.
Future investigations may establish such a
causal role advancing our understanding
of the complex pathogenic mechanisms
underlying FGR.
n

Limitations of the study
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